Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00348790
Other study ID # NU 05C4
Secondary ID STU00005338NU 05
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2006
Est. completion date July 2013

Study information

Verified date October 2018
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.


Description:

OBJECTIVES:

Primary

- Determine the efficacy of vatalanib, in terms of radiographic improvement and clinical improvement, in patients with recurrent or progressive meningioma.

Secondary

- Determine the 6-month progression-free survival of these patients.

- Describe the response rate and overall survival of these patients.

- Determine the safety of vatalanib in these patients.

- Correlate the response rates with expression of vascular endothelial growth factor, epidermal growth factor receptor, platelet-derived growth factor, and HER2.

- Develop exploratory data concerning surrogate markers of angiogenic activity in vivo using magnetic resonance perfusion.

OUTLINE: Patients receive oral vatalanib twice daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 1 year.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date July 2013
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed meningioma, including the following subtypes:

- Benign meningioma

- Malignant meningioma

- Steroid dosage stable for = 5 days

- Atypical meningiomas

- Hemangiopericytoma

- May or may not have neurofibromatosis (NF) type 1 or 2 disease

- Patients with a history of NF may have other stable CNS tumors, such as schwannoma, acoustic neuroma, or ependymoma only if those lesions have been stable for the past 6 months

- Progressive or recurrent disease by MRI or CT scan

- Prior radiotherapy allowed provided evidence of disease progression is documented by positron emission tomography, thallium scanning, magnetic resonance spectroscopy, or surgery to rule out radiation necrosis for patients treated with radiosurgery

- Recent resection of recurrent or progressive tumor allowed provided both of the following criteria are met:

- At least 4 weeks since prior surgery and recovered

- Evaluable residual disease

PATIENT CHARACTERISTICS:

- Karnofsky performance status 60-100%

- Life expectancy > 12 weeks

- Absolute neutrophil count = 2,000/mm³

- Platelet count = 100,000/mm³

- Hemoglobin = 10 g/dL (transfusion allowed)

- SGOT and SGPT < 2 times upper limit of normal (ULN)

- Bilirubin = 1.5 times ULN

- Creatinine < 1.5 mg/dL

- Negative proteinuria dipstick OR total urinary protein = 500 mg AND creatinine clearance = 50 mL/min

- PT, INR, and PTT = 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for up to 6 months after completion of study treatment

- No history of any other cancer except nonmelanoma skin cancer or carcinoma in situ of the cervix, unless in complete remission and off all therapy for that disease for = 3 years

- No disease that would obscure toxicity or dangerously alter drug metabolism

- No bleeding disorders

- No severe and/or uncontrolled medical conditions that would limit compliance with study requirements, including any of the following:

- Uncontrolled high blood pressure

- History of labile hypertension

- History of poor compliance with an antihypertensive regimen

- Unstable angina pectoris

- Symptomatic congestive heart failure

- Myocardial infarction within the past 6 months

- Serious uncontrolled cardiac arrhythmia

- Uncontrolled diabetes

- Active or uncontrolled infection

- Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of vatalanib (i.e., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow tablets)

- QTc > 450 (male) or > 470 (female)

- Congenital or acquired long QTc syndrome

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy

- At least 4 weeks since prior radiotherapy, including external-beam radiotherapy, interstitial brachytherapy, or gamma-knife radiosurgery

- At least 4 weeks since prior investigational agents

- More than 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)

- More than 4 weeks since prior immunotherapy

- More than 2 weeks since prior noncytotoxic or biologic therapies

- At least 2 weeks since prior drugs that affect hepatic metabolism (steroids should be tapered off if not clinically indicated)

- At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsant drugs

- No prior antivascular endothelial growth factor therapy

- No other concurrent investigational agents or anticancer therapy (including chemotherapy, radiotherapy, hormonal therapy, or immunotherapy)

- No concurrent warfarin

- No concurrent grapefruit or grapefruit juice

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
vatalanib


Locations

Country Name City State
United States Hematology-Oncology Associates of Illinois Chicago Illinois
United States Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois
United States University Cancer Center at University of Washington Medical Center Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Develop Data Concerning Certain Genes That Cause Tumors to Grow New Blood Vessels Data concerning certain genes that cause tumors to grow new blood vessels will be examined by MRI scan with MR Perfusion done before treatment and then every 2 months while on study treatment MRI with MR Perfusion will be done before treatment and then every 2 months while on study treatment
Other To Use the FACT BR Questionnaire to Measure Quality of Life FACT BR questionnaire will be used to measure quality of life at baseline and then every time an MRI scan is performed while on study treatment At baseline and then every time an MRI is performed while on study treatment.
Primary Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted. From the date the first patient began treatment until the date the last patient has disease progression, becomes deceased, or completes 6 months of treatment
Secondary Determine Efficacy (Radiographic and Clinical Improvement) Efficacy will be assessed by MRI scan and neurological exam upon study entry, every 2 weeks for 2 months, then every 8 weeks while on treatment At baseline, every 2 weeks for 2 months, then every 8 weeks while on treatment
Secondary Best Overall Response Rate (ORR) Overall Response Rate (ORR) will be as assessed by MRI scan every 2 months while on study treatment and follow-up for up to 1 year after discontinuation of study treatment. The RR is the best response recorded from the start of the treatment until disease progression (PD) where the following definitions apply.
Complete Response (CR): Complete disappearance of all measurable and evaluable disease. No new lesions.
Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.
Stable/No Response: Does not qualify for CR, PR, or PD Progressive disease (PD):25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) worsening of evaluable disease, new lesions, clinical worsening OR failure to return for evaluation due to death/deteriorating condition
Every 2 months for up to 1 year after study treatment.
Secondary To Correlate the Response Rates With Expression of Certain Types of Genes Correlation of response rates with the expression of certain types of genes will be assessed by examining tissue samples taken from previous surgery and testing for certain genes At the end of study treatment
Secondary Safety of Vatalanib in Patients With Recurrent of Progressive Meningiomas Safety of vatalanib will be assessed using National Cancer Institute Common Terminology Criteria of Adverse Events (NCI CTCAE) 3.0 and graded using the following:
Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Fatal
Every week while on study treatment until 30 days after last treatment.
Secondary Number of Months Patients Survive After Being Treatment on the Study. From the date the first patient began treatment until the date the last patient became deceased.
Secondary Overall Survival (OS) Overall Survival will be measured from the first treatment on study until death of any cause. Every 2 months for up to 1 year after study treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2